Private Equity Track record
  • Quintiles
    North America / Private Equity



    Quintiles delivered transformational growth to become the world’s largest provider of life sciences product development and integrated healthcare services. It helps biopharmaceutical customers, as well as other healthcare customers, navigate the increasingly complex healthcare environment to improve efficiency and deliver better healthcare outcomes.

    During our ownership, Quintiles expanded its commercial services into the Middle East, North Africa and East Africa, and developed numerous clinical development and joint venture partnerships. The business also expanded its Real-World & Late Phase offering through acquisitions and strategic partnerships. Quintiles has an extensive reach and has helped develop or commercialise most of the top biopharmaceutical and biologic products on the market today.

    In November 2017, post 3i’s exit, Quintiles adopted the name of IQVIA


    • Completed nine acquisitions
    • Near doubling of revenue from $2.8bn to $4.5bn; EBITDA grew over 250%
    • Expanded the global employee base from c 20,000 to c 35,000 employees
    • Listed on the NYSE in May 2013, becoming a member of the FORTUNE 500, and named in FORTUNE’s list of the “World’s Most Admired Companies”
    “We are proud to have supported the business and its management team during this period of transformational growth and would like to thank them for their partnership over the years.” Richard Relyea, Partner, 3i North America

    Regulatory information 
    This transaction involved a recommendation of 3i Corporation, a US wholly owned subsidiary of 3i Group. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this release. For data relating to other assets involving a past recommendation by 3i Corporation please click here.

Back to top